Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 32,196 | 30,888 | -21,269 | 28,075 | 54,167 |
| Cost of Goods | 1,452 | 4,145 | -883 | 1,114 | 2,051 |
| Gross Profit | 30,744 | 26,743 | -20,386 | 26,961 | 52,116 |
| Operating Expenses | 135,147 | 124,257 | 84,359 | 109,679 | 117,618 |
| Operating Income | -103,951 | -97,369 | -105,628 | -82,604 | -65,451 |
| Interest Expense | 2,843 | 2,850 | 2,698 | 2,829 | 2,972 |
| Other Income | 4,927 | 3,733 | 3,987 | 1,515 | 1,444 |
| Pre-tax Income | -101,867 | -96,486 | -104,339 | -83,918 | -66,979 |
| Income Tax | 65 | 78 | 63 | 145 | 53 |
| Net Income Continuous | -101,932 | -96,564 | -104,402 | -84,063 | -67,032 |
| Net Income Discontinuous | 16,302 | 10,233 | 38,579 | 14,407 | N/A |
| Net Income | $-85,630 | $-86,331 | $-65,823 | $-69,656 | $-67,032 |
| EPS Basic Total Ops | -1.13 | -1.27 | -1.03 | -1.09 | -1.05 |
| EPS Basic Continuous Ops | -1.34 | -1.42 | -1.63 | -1.31 | -1.05 |
| EPS Basic Discontinuous Ops | 0.21 | 0.15 | 0.61 | 0.22 | N/A |
| EPS Diluted Total Ops | -1.13 | -1.27 | -1.03 | -1.09 | -1.05 |
| EPS Diluted Continuous Ops | -1.34 | -1.42 | -1.63 | -1.31 | -1.05 |
| EPS Diluted Discontinuous Ops | 0.21 | 0.15 | 0.61 | 0.22 | N/A |
| EBITDA(a) | $-93,004 | $-90,749 | $-98,717 | $-83,969 | $-56,448 |